GSK2586881
Phase 2Small molecule
GSKGSK2586881 is one of 117 small molecule programs targeting Fibrosis. It is currently in Phase 2.
3
Indications
2
Total Trials
0
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
179 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
Levitra
BayerPhase 3
Reata
BiogenPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Flolan
Johnson & JohnsonPhase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Atrovent
Boehringer IngelheimPhase 3
Inhaled Iloprost
BayerPhase 3
Actemra
RochePhase 2
Bayer Aspirin
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GSK2586881. EMBL-EBI & Wellcome Sanger Institute.
- [4]